Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 6/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | RORB | Q92753 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21518072 | 0.94 | CES2 (0.48) | CES2CES1RORCPTGS2ALB | |
| SCHEMBL504216 | 0.87 | CA12 (0.46) | ALDH1A1HPGDTAS2R14 | |
| SCHEMBL23908702 | 0.83 | ALDH1A1 (0.51) | CES1ALDH1A1HPGDTAS2R14 | |
| SCHEMBL30313345 | 0.82 | CES2 (0.48) | CES2CES1RORCPTGS2RORB | |
| SCHEMBL716995 | 0.82 | CES2 (0.48) | CES2CES1RORCPTGS2RORB | |
| SCHEMBL18131338 | 0.82 | CES2 (0.48) | CES2CES1ALBALDH1A1KCNN4 | |
| SCHEMBL476764 | 0.82 | CES2 (0.48) | CES2CES1RORCPTGS2CYP3A4 | |
| SCHEMBL3708513 | 0.82 | CES2 (0.48) | CES2CES1RORCPTGS2ITGA4 | |
| SCHEMBL19585735 | 0.82 | DAO (0.42) | CES2CES1RORCALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL4371024 | 0.81 | CES2 (0.47) | CES2CES1RORCPTGS2ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| CN-119431706-A | Fatigue-resistant polyurethane elastomer and preparation method and application thereof | 万勋科技(深圳)有限公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-116836081-A | Ether epoxy toughening agent and preparation method and application thereof | 中国林业科学研究院林产化学工业研究所 | 2023-10-03 | — | — | CN | claimed |
| CN-112679374-A | Preparation method of 2-fluoro-6- (trifluoromethyl) benzamide | 湖南复瑞生物医药技术有限责任公司 | 2021-04-20 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-111909040-A | Preparation method of Elagolix intermediate 2-fluoro-6-trifluoromethylbenzylamine | 南京莱克施德药业有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-107681052-B | Main group metal complexes as p-dopants for organic electronic matrix materials | 西门子公司 | 2020-03-24 | — | — | CN | claimed |
| US-10483466-B2 | P-doping cross-linking of organic hole transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2019-11-19 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-3985799-A | 2-Fluoro-6-trifluoromethylbenzoic acid | SANDOZ, INC. (US) | 1976-10-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | CES2 1598/4885CES1 3489/4885RORC 1332/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | CES2 2351/4885CES1 3786/4885RORC 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.